Match!
William Tappe
ImmunologyHematopoietic stem cell transplantationDefibrotideHepatic veno-occlusive diseaseMedicine
26Publications
2H-index
19Citations
What is this?
Publications 32
Newest
#1Selim Corbacioglu (University of Regensburg)H-Index: 15
#2Nancy A. Kernan (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 56
Last. Paul G. Richardson (Harvard University)H-Index: 156
view all 6 authors...
Abstract Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of hematopoietic cell transplantation (HCT) that is traditionally diagnosed using Baltimore or modified Seattle criteria. While Baltimore criteria require the presence of hyperbilirubinemia (bilirubin ≥2 mg/dL) for diagnosis of VOD/SOS, modified Seattle criteria do not. Prior to approval by the US Food and Drug Administration, defibrotide was available in the US through an exp...
Source
#1Paul G. Richardson (Harvard University)H-Index: 156
#2Angela Smith (UMN: University of Minnesota)H-Index: 29
Last. Stephan A. Grupp (Children's Hospital of Philadelphia)H-Index: 57
view all 8 authors...
For patients with untreated hepatic veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) with multi-organ dysfunction (MOD), mortality is >80%. We conducted a pooled analysis of three studies that assessed Day 100 survival in relationship to MOD severity, with dialysis and/or ventilator dependence representing the most severe organ dysfunction. All patients in the analysis were diagnosed using Baltimore criteria/biopsy. This analysis of patients with VOD/SOS and MOD after haematopo...
Source
Introduction Defibrotide (DF) is approved for adult and pediatric patients (pts) with hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) with renal or pulmonary dysfunction after hematopoietic cell transplantation (HCT) in the United States and Canada, and for severe hepatic VOD/SOS post-HCT in patients aged >1 month in the European Union. The recommended dose is 25 mg/kg/day given as a 2-hour intravenous (IV) infusion in 4 divided doses. Several studies have examined wheth...
Source
Introduction Defibrotide (DF) is approved for adult and pediatric patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) with renal or pulmonary dysfunction after hematopoietic cell transplantation (HCT) in the United States. The recommended dose is 6.25 mg/kg every 6 hours given as a 2-hour intravenous (IV) infusion. In vitro, DF reduces activation of endothelial cells, promotes fibrinolytic enzymes, and exhibits antithrombotic properties. Post-HCT patients with ...
Source
#1William TappeH-Index: 2
#2Saurabh AggarwalH-Index: 1
Last. Massimo IacobelliH-Index: 16
view all 4 authors...
Source
#1Vincent T. Ho (Harvard University)H-Index: 71
Last. William TappeH-Index: 2
view all 4 authors...
Source
#1Paul G. Richardson (Harvard University)H-Index: 156
#2Enric CarrerasH-Index: 45
Last. Mohamad Mohty (University of Paris)H-Index: 54
view all 6 authors...
Introduction Hepatic VOD/SOS is a potentially life-threatening complication of HSCT or nontransplant chemotherapy. VOD/SOS with multi-organ dysfunction (MOD; eg, renal or pulmonary) may be associated with >80% mortality. DF is approved to treat hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the US and Canada, and severe hepatic VOD/SOS post-HSCT in patients aged >1 month in the EU. Methods Data from the international compassionate use program (CUP) and expanded-access protocol ...
Source
#1Selim Corbacioglu (University of Regensburg)H-Index: 15
#2Nancy A. Kernan (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 56
Last. Paul G. Richardson (Harvard University)H-Index: 156
view all 6 authors...
Introduction Hepatic VOD/SOS is a progressive, potentially life-threatening complication of HSCT or nontransplant chemotherapy. VOD/SOS diagnosis by Baltimore criteria requires bilirubin >2 mg/dL; hyperbilirubinemia is not required by modified Seattle criteria, and may be a late finding in the progression of VOD/SOS. DF is approved to treat hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the US and Canada, and to treat severe hepatic VOD/SOS post-HSCT in patients (pts) aged >1 m...
Source
#1Selim Corbacioglu (University of Regensburg)H-Index: 15
#2Nancy A. Kernan (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 56
Last. Paul G. Richardson (Harvard University)H-Index: 156
view all 6 authors...
Introduction Hepatic VOD/SOS is a progressive, potentially life-threatening complication early post-HSCT, or of nontransplant chemotherapy. VOD/SOS diagnosis has been based on Baltimore (≤21 days post-HSCT and bilirubin ≥2 mg/dL plus ≥2 of: hepatomegaly, ascites, weight gain ≥5%) or modified Seattle (≤20 days post-HSCT and ≥2 of: bilirubin >2 mg/dL, hepatomegaly or right upper quadrant pain, weight gain [>5% in defibrotide studies]) criteria. Recent European Society of Blood and Marrow Transplan...
Source
#1Paul G. Richardson (Harvard University)H-Index: 156
#2Enric CarrerasH-Index: 45
Last. Mohamad MohtyH-Index: 54
view all 6 authors...
Introduction Hepatic VOD/SOS is a potentially life-threatening complication of HSCT or of nontransplant-associated high-dose chemotherapy. VOD/SOS associated with multi-organ dysfunction (MOD; eg, renal or pulmonary dysfunction) may be associated with >80% mortality. Defibrotide is approved to treat hepatic VOD/SOS with renal and/or pulmonary dysfunction post-HSCT in the United States and Canada, and to treat severe hepatic VOD/SOS post-HSCT in patients aged >1 month in the European Union. Prior...
Source
1234